Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for ABBV, BKKT and MULN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Wednesday, 11 May 2022 09:45 AM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 11, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ABBV Shareholders Click Here: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=27099&wire=1
BKKT Shareholders Click Here: https://www.zlk.com/pslra-1/bakkt-holdings-inc-f-k-a-vpc-impact-acquisition-holdings-loss-submission-form?prid=27099&wire=1
MULN Shareholders Click Here: https://www.zlk.com/pslra-1/mullen-automotive-inc-f-k-a-net-element-inc-loss-submission-form?prid=27099&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, May 11, 2022, Press release picture

AbbVie Inc. (NYSE:ABBV)

ABBV Lawsuit on behalf of: investors who purchased April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline : June 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=27099&wire=1

According to the filed complaint, during the class period, AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings (NYSE:BKKT)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Bakkt securities between March 31, 2021 and November 19, 2021, both dates inclusive; and/or (b) Bakkt Class A common stock pursuant and/or traceable to documents issued in connection with the business combination between the Company and Bakkt Holdings, LLC completed on or about October 15, 2021.
Lead Plaintiff Deadline : June 20, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bakkt-holdings-inc-f-k-a-vpc-impact-acquisition-holdings-loss-submission-form?prid=27099&wire=1

According to the filed complaint, (i) the Company had defective financial controls; (ii) as a result, there were errors in the Company's financial statements related to the misclassification of certain shares issued prior to the business combination between the Company and Bakkt Holdings, LLC; (iii) accordingly, the Company would need to restate certain of its financial statements; (iv) the Company downplayed the true scope and severity of these issues; (v) the Company overstated its remediation of its defective financial controls; and (vi) as a result, the documents issued in connection with the business combination and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Mullen Automotive, Inc. f/k/a Net Element, Inc. (NASDAQ:MULN)

MULN Lawsuit on behalf of: investors who purchased June 15, 2020 - April 6, 2022
Lead Plaintiff Deadline : July 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mullen-automotive-inc-f-k-a-net-element-inc-loss-submission-form?prid=27099&wire=1

According to the filed complaint, during the class period, Mullen Automotive, Inc. f/k/a Net Element, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Mullen overstates its ability and timeline regarding production; (2) Mullen overstates its deals with business partners, including Qiantu; (3) Mullen overstates its battery technology and capabilities; (4) Mullen overstates its ability to sell its branded products; (5) Net Element did not conduct proper due diligence into Mullen Technologies; (6) the Dragonfly K50, a luxury sports car, was not (solely) delayed due to the COVID-19 pandemic; and (7) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: